Mitochondrial Dysfunction
Impaired mitochondrial function leading to inadequate cellular energy production and increased oxidative stress. Mitochondrial dysfunction contributes to many diseases including neurodegenerative conditions, metabolic disorders, and ageing. Elamipretide represents the first approved peptide targeting mitochondrial biology.
Technical Context
Mitochondrial dysfunction spectrum: primary mitochondrial diseases (genetic defects in mtDNA or nuclear genes encoding mitochondrial proteins — over 300 causative genes identified; Barth syndrome is one example; others include Leigh syndrome, MELAS, MERRF), and secondary mitochondrial dysfunction (mitochondrial impairment as a consequence of other disease processes — neurodegenerative diseases, diabetes, heart failure, ageing). Diagnostic indicators: elevated lactate (anaerobic glycolysis compensating for impaired oxidative phosphorylation), elevated lactate/pyruvate ratio, respiratory chain enzyme activities (measured in muscle biopsy), mtDNA sequencing, and advanced imaging (MR spectroscopy detecting brain lactate). Elamipretide represents the first approved drug targeting mitochondrial biology via cardiolipin stabilisation. Other mitochondrial therapeutic approaches in development: gene therapy for mtDNA mutations, ETC bypass molecules (idebenone), NAD+ precursors (nicotinamide riboside), and mitochondrial-targeted antioxidants (MitoQ, SkQ1).